ConductScience.org, home

Comparison · NCT03030599-f367e6c2

JZP-258 vs Placebo: Number of Participants With Worsening Patient Global Impression of Change (PGIc) for Narcolepsy Overall

Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.

2 sourcestrial-comparisons-2026-03-23-0.1.0

Download JSON
Cite this record

ConductScience Library. JZP-258 vs Placebo: Number of Participants With Worsening Patient Global Impression of Change (PGIc) for Narcolepsy Overall. Trial comparisons, record NCT03030599-f367e6c2. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT03030599-f367e6c2

On this page

Measures6

Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.

MeasureValue95% interval, lower95% interval, upperMethodNote
Risk in group 10.04350.01490.12wilson
Risk in group 20.4460.3320.567wilson
Risk difference, group 1 minus group 2-0.403-0.526-0.265newcombe hybrid score
Risk ratio, group 1 over group 20.09750.03120.305log
Odds ratio, group 1 over group 20.05640.01610.198log
Number needed to treat, for one fewer participant with the outcome on JZP-258 than on Placebo2.481.93.78from the risk difference interval

Groups2

Group 2 names the comparator: placebo.

GroupTitleDescriptionWith the outcomeAnalysedClinicalTrials.gov code
Group 1JZP-258JZP-258 at the dose taken during the last 2 weeks of the Stable Dose Period.369OG000
Group 2PlaceboA matching oral solution to JZP-258.2965OG001

Outcome

Type
SECONDARY
Title
Number of Participants With Worsening Patient Global Impression of Change (PGIc) for Narcolepsy Overall
Description
At the end of the Double Blind Randomized Withdrawal Period (DB RWP), participants rated the change in their condition on a 7-point scale ranging from 1 = very much improved to 7 = very much worse since the last visit. This endpoint measures the percentage of participants with worsening PGIc scores for narcolepsy overall (defined as scores of Much Worse or Very Much Worse).
Time frame
At the end of the Double Blind Randomized Withdrawal Period
Population
The efficacy population contains all randomized subjects who received at least one dose of double-blind study drug and had at least one set of post-randomization efficacy data.

Source ClinicalTrials.gov

Trial

Title
A Study of the Efficacy and Safety of JZP-258 in Subjects With Narcolepsy With Cataplexy
NCT number
NCT03030599
Phases
PHASE3
Conditions
Narcolepsy With Cataplexy
Interventions
JZP-258, Placebo
Lead sponsor
Jazz Pharmaceuticals
Results first posted
2020-11-12

Source ClinicalTrials.gov

Source

Release
trial-comparisons-2026-03-23-0.1.0
Release manifest SHA-256
f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
AACT copy
2026-03-23
Tables read
outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet

Source ClinicalTrials.gov

Sources 2

  • ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
  • ClinicalTrials.govNo license stated
Each source's terms
  • ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
  • ClinicalTrials.govnone stated

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.

For software

Read this comparison from software.

The record is JSON. No key.

GET https://conductscience.org/api/comparisons/v1/NCT03030599-f367e6c2